Study #2025-1815
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T cell therapy, versus standard regimens in adult participants with relapsed or refractory and Lenalidomide-exposed multiple myeloma (QUINTESSENTIAL-2)
MD Anderson Study Status
Enrolling
Treatment Agent
BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
Description
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed or Refractory Multiple Myeloma (RRMM)
Study phase:
Phase III
Physician name:
Oren Pasvolsky
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?